Intra-Cellular Therapies EBITDA 2013-2022 | ITCI
Intra-Cellular Therapies annual and quarterly EBITDA history from 2013 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Intra-Cellular Therapies EBITDA for the quarter ending March 31, 2022 was $-0.077B, a 41.33% increase year-over-year.
- Intra-Cellular Therapies EBITDA for the twelve months ending March 31, 2022 was $-0.312B, a 31.88% increase year-over-year.
- Intra-Cellular Therapies 2021 annual EBITDA was $-0.289B, a 25.02% increase from 2020.
- Intra-Cellular Therapies 2020 annual EBITDA was $-0.231B, a 49.58% increase from 2019.
- Intra-Cellular Therapies 2019 annual EBITDA was $-0.155B, a 5.02% decline from 2018.
Intra-Cellular Therapies Annual EBITDA
(Millions of US $) |
| 2021 |
$-289 |
| 2020 |
$-231 |
| 2019 |
$-155 |
| 2018 |
$-163 |
| 2017 |
$-102 |
| 2016 |
$-118 |
| 2015 |
$-105 |
| 2014 |
$-31 |
| 2013 |
$-26 |
| 2012 |
$-16 |
Intra-Cellular Therapies Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$-77 |
| 2021-12-31 |
$-87 |
| 2021-09-30 |
$-79 |
| 2021-06-30 |
$-70 |
| 2021-03-31 |
$-54 |
| 2020-12-31 |
$-62 |
| 2020-09-30 |
$-56 |
| 2020-06-30 |
$-65 |
| 2020-03-31 |
$-49 |
| 2019-12-31 |
$-42 |
| 2019-09-30 |
$-36 |
| 2019-06-30 |
$-39 |
| 2019-03-31 |
$-37 |
| 2018-12-31 |
$-43 |
| 2018-09-30 |
$-44 |
| 2018-06-30 |
$-39 |
| 2018-03-31 |
$-37 |
| 2017-12-31 |
$-33 |
| 2017-09-30 |
$-24 |
| 2017-06-30 |
$-18 |
| 2017-03-31 |
$-28 |
| 2016-12-31 |
$-28 |
| 2016-09-30 |
$-30 |
| 2016-06-30 |
$-31 |
| 2016-03-31 |
$-28 |
| 2015-12-31 |
$-29 |
| 2015-09-30 |
$-32 |
| 2015-06-30 |
$-21 |
| 2015-03-31 |
$-22 |
| 2014-12-31 |
$-15 |
| 2014-09-30 |
$-6 |
| 2014-06-30 |
$-5 |
| 2014-03-31 |
$-5 |
| 2013-12-31 |
$-8 |
| 2013-09-30 |
$-5 |
| 2013-06-30 |
$-8 |
| 2013-03-31 |
$-5 |
| 2012-12-31 |
|
| 2012-09-30 |
$-2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.373B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
